Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery

• Published in: Journal of drug targeting Vol. 15; no. 10; pp. 641 - 663
• Main Authors: Vauthier, Christine, Labarre, Denis, Ponchel, Gilles
• Format: Journal Article
• Language: English
• Published: Abington Informa UK Ltd 01.01.2007; Taylor & Francis; Informa Healthcare
• Subjects: biodistribution; Bioengineering; Biological and medical sciences; Biomaterials; Cyanoacrylates - administration & dosage; Cyanoacrylates - chemical synthesis; Delayed-Action Preparations; Drug carrier; Drug Carriers - administration & dosage; Drug Carriers - chemical synthesis; Drug Design; Emulsions; Galenic pharmacology; General pharmacology; Life Sciences; Medical sciences; Nanocapsules; nanoparticle; nanoparticle surface; Nanoparticles; Nanospheres; Pharmaceutical sciences; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; poly(alkylcyanoacrylate); Polymers; Drug; Nanocapsule; biodistribution; Pharmaceutical technology; Nanoparticle; Alkyl acrylate(cyano) copolymer; nanocapsules; Drug carrier; poly(alkylcyanoacrylate); Research and development; Design; Distribution; nanoparticle surface; Microparticle; Pharmacokinetics; in vivo fate; nanoparticle; nanosphere; drug carrier
• ISSN: 1061-186X; 1029-2330
• DOI: 10.1080/10611860701603372

Poly(alkylcyanoacrylate) (PACA) nanoparticles were first developed 25 years ago taking advantage of the in vivo degradation potential of the polymer and of its good acceptance by living tissues. Since then, various PACA nanoparticles were designed including nanospheres, oil-containing and water-containing nanocapsules. This made possible the in vivo delivery of many types of drugs including those presenting serious challenging delivery problems. PACA nanoparticles were proven to improve treatments of severe diseases like cancer, infections and metabolic disease. For instance, they can transport drugs accross barriers allowing delivery of therapeutic doses in difficult tissues to reach including in the brain or in multidrug resistant cells. This review gives an update on the more recent developments and achievements on design aspects of PACA nanoparticles as delivery systems for various drugs to be administered in vivo by different routes of administration.